Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01846143 · ClinicalTrials.gov registry record · Phase 1
Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies
A Phase 1 study, sponsored by Craig L Slingluff, Jr.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01846143 is a Phase 1 study that has completed, run by Craig L Slingluff, Jr. The registered enrollment target is 15 participants.
The verdict
NCT01846143, a Phase 1 study, has completed, sponsored by Craig L Slingluff, Jr.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to learn what effects (good and bad) experimental phosphopeptide vaccines plus a tetanus peptide and other substances called polyICLC and Montanide ISA-51 have on people with melanoma. The investigators will also look at whether the experimental reagents cause any changes in the immune system.
Interventions
- BIOLOGICAL pBCAR3-phosphopeptide
- BIOLOGICAL pIRS2-phosphopeptide
- BIOLOGICAL 2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01846143
The ClinicalTrials.gov registry entry for NCT01846143 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Craig L Slingluff, Jr, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which pBCAR3-phosphopeptide is the first listed.
NCT01846143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01846143 about?
NCT01846143 is a clinical study titled "Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies". The purpose of this study is to learn what effects (good and bad) experimental phosphopeptide vaccines plus a tetanus peptide and other substances called polyICLC and Montanide ISA-51 have on people with melanoma. The investigators will also look at whether the experimental reagents cause any change...
What is the current status of trial NCT01846143?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2013-05. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01846143?
The interventions under investigation include: pBCAR3-phosphopeptide (BIOLOGICAL), pIRS2-phosphopeptide (BIOLOGICAL), 2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01846143?
This trial is sponsored by Craig L Slingluff, Jr, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.